Short answer
Enliven Therapeutics, Inc. (ELVN) filed its fiscal 2025 10-K annual report with the SEC on Mar 3, 2026.
- Top risk flagged: FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies
FY2025 key financial metrics · XBRL
- Net income
- −$104M
- −16.5% YoY
- EPS (diluted)
- −$1.83
- +3.2% YoY
- ROE
- -22.6%
- +6.2 pp YoY
- Operating cash flow
- −$70M
- +3.9% YoY
Source: XBRL data from the Enliven Therapeutics, Inc. (ELVN) FY2025 10-K on SEC EDGAR. USD.
Enliven Therapeutics, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage biopharma developing selective small molecule therapeutics targeting validated biology using precision medicine
- New emphasis on ELVN-001, a selective ATP-competitive BCR-ABL TKI for CML addressing resistance, off-target toxicity, and dosing challenges
- Strategic pivot to prioritize ELVN-001; exploring strategic alternatives for ELVN-002 to focus resources on lead program
- ENABLE Phase 1 trial enrolled 90 patients; 47% cumulative MMR rate by 24 weeks with favorable safety in heavily pretreated CML patients
- CEO Rick Fair joined Dec 2025, bringing 25+ years pharma leadership including commercial launches for $23B oncology portfolio
Management Discussion & Analysis
- No revenue generated in FY 2025 or 2024; no expected revenue in foreseeable future
- Net loss $103.7M in 2025 vs $89.0M in 2024; operating expenses $119.7M vs $104.6M; operating margin negative and worsening
- R&D increased to $85.9M in 2025 from $80.8M in 2024; ELVN-001 external costs up $7.8M, ELVN-002 external costs down $12.8M; G&A rose to $33.8M from $23.8M driven by $9.6M higher stock comp
- Cash, cash equivalents and marketable securities $462.6M at December 31, 2025; raised $230M in June 2025 Public Offering, $90M in March 2024 Private Placement, $40M via Sales Agreement through 12/31/2025
- Management expects operating losses and R&D expenses to increase; cash runway covers at least next 12 months; key risks include clinical trial progress, regulatory approval, need for further capital raises, and macroeconomic/geopolitical uncertainties
Risk Factors
- FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies
- Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact
- Supply chain vulnerability: changes in manufacturing process require FDA comparability analysis and approval, possibly delaying clinical trials
- Competitive risk: dependency on ELVN-001 amid high biopharma attrition rates and competing therapies impacting commercial acceptance
- Financial risk: accumulated deficit $347.2M, net loss $103.7M in 2025, need for substantial additional funding to sustain operations
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.